DEA Proposes Changes to Drug Quota Applications
Published Date: 5/20/2026
Proposed Rule
Summary
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
New Quota Application Timeline Reporting
If you are a bulk or non-bulk manufacturer applying for DEA quotas, you must provide new production-timeline details on quota applications (DEA Form 189 for bulk manufacturers; DEA Form 250 for non-bulk manufacturers). DEA lists the required items: desired individual manufacturing quota (bulk only), time to start production after receiving DEA's quota letter, time to receive API after quota letter (procurement), time to perform the production cycle, time to ship finished goods to the next registrant, supplier of the basic class/chemical (if from another registrant), and any additional relevant factors.
Better Data to Prevent Drug Shortages
DEA says the new application information and subcategory changes will give the agency better visibility into manufacturing cycles and domestic vs. export use, enabling DEA to adjust quotas more quickly to anticipate and help prevent drug shortages that affect medical and scientific needs.
Domestic vs. Export Quota Split
DEA will split certain quota subcategories so manufacturers must state whether quota is for domestic use or for lawful export. The rule bifurcates 'Quota for Commercial Sale', 'Quota for Product Development', and 'Quota for Packaging/Repackaging and Labeling/Relabeling' into domestic and export subcategories (e.g., 'Quota for Domestic Commercial Sale' and 'Quota for Commercial Manufacturing for Export').
Estimated Time and Dollar Burden
DEA estimates the new information will add about 20 minutes per DEA Form 189 or 250 to complete, with a loaded median hourly cost of $89.42 for a purchasing manager, producing an estimated per-application cost of $29.81. Using 2022 application counts (875 Form 189 and 2,514 Form 250), DEA estimates an annual total cost of $101,026.
Small-Entity Impact Finding
DEA certifies under the Regulatory Flexibility Act that the proposed rule will not have a significant economic impact on a substantial number of small entities. DEA estimates the rule would affect 38 of 635 small entities in NAICS 325411 and 272 of 1,080 small entities in NAICS 325412, with estimated economic impacts of 0.095% and 0.022% of annual receipts for those industries, respectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
Previous / Next Documents
Previous: 2026-10086 — Extending the Compliance Deadline for the PFOA and PFOS Maximum Contaminant Levels
The EPA is giving water systems more time to meet safety rules for two harmful chemicals, PFOA and PFOS, by extending the deadline from April 2029 to April 2031 if they ask for it. This helps water providers get ready without rushing, keeping our drinking water safe. The EPA wants your thoughts and will hold a public hearing in July 2026 to hear from everyone.
Next: 2026-10161 — Significant New Use Rules on Certain Chemical Substances (26-2); Extension of Comment Period
The EPA is giving folks more time to share their thoughts on new rules about certain chemicals. If you make, import, or use these chemicals in new ways, you have to tell the EPA 90 days before starting. The comment deadline is now July 10, 2026, so don’t miss your chance to speak up!